Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) saw a significant decrease in short interest in February. As of February 15th, there was short interest totalling 106,900 shares, a decrease of 22.0% from the January 31st total of 137,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is presently 0.1 days. Approximately 3.9% of the shares of the stock are sold short.

Palisade Bio Stock Performance

Shares of NASDAQ:PALI opened at $0.83 on Tuesday. The company has a fifty day moving average of $1.42 and a 200-day moving average of $2.46. The company has a market capitalization of $2.29 million, a PE ratio of -0.06 and a beta of 1.43. Palisade Bio has a 52-week low of $0.80 and a 52-week high of $9.65.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Maxim Group lowered their price target on shares of Palisade Bio from $22.50 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Brookline Capital Management assumed coverage on shares of Palisade Bio in a report on Wednesday, November 20th. They set a “buy” rating and a $38.00 price target for the company.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Palisade Bio stock. Cetera Investment Advisers acquired a new position in Palisade Bio, Inc. (NASDAQ:PALI) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 70,006 shares of the company’s stock, valued at approximately $116,000. Cetera Investment Advisers owned about 2.53% of Palisade Bio as of its most recent SEC filing. Institutional investors and hedge funds own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.